secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROKIDNEY CORP. (PROK)
CIK:        0001850270
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021256
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProKidney Q1 net loss $36.9M, cash $463.7M; Phase 2 REACT enrollment complete
-----------------------------------------------------------------------------

- Net loss before noncontrolling interest $36.9M vs $67.5M in Q1 2022; R&D spend $25.6M.
- Cash, cash equivalents and marketable securities $463.7M as of March 31, 2023.
- Completed enrollment in REGEN-007 Phase 2 study (53 subjects); initial data expected late 2023.
- Phase 3 proact 1 enrollment ongoing; interim data targeted by end of 2024.
- Preparing to initiate proact 2 Phase 3 study in EU, Latin America, Asia Pacific in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/0000950170-23-021256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/prok-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer